Subcutaneous

Jasper Therapeutics Highlights Recent Accomplishments and Key Upcoming Milestones

Retrieved on: 
Friday, January 5, 2024
Omalizumab, Subcutaneous, CD117, Risk, IND, EMA, FA, Chairperson, Cold urticaria, Therapy, MDS, Chronic, Fanconi anemia, ASH, Annual general meeting, European Medicines Agency, Syndrome, CSU, SVP, Patient, Acute myeloid leukemia, Safety, AML, CTA, Pharmaceutical industry

REDWOOD CITY, Calif., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) in mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), as well as lower to intermediate risk myelodysplastic syndromes (LR-MDS) and novel stem cell transplant conditioning regimens, today announced its recent accomplishments, including the authorization by the European Medicines Agency (EMA) of the Company’s Clinical Trial Applications (CTA) for its Phase 1b/2a trials of briquilimab in CIndU and CSU, and outlined its corporate priorities and anticipated milestones for 2024. Called SPOTLIGHT – “Study (Phase 1b/2a) Of subcuTaneous brIquilimab in patients diaGnosed with cHronic inducible urTicaria” – the CIndU study will evaluate single doses of subcutaneous briquilimab in adult patients with cold urticaria or symptomatic dermographism.

Key Points: 
  • “2023 was a strategically important year for Jasper,” said Ronald Martell, President and Chief Executive Officer of Jasper.
  • “We secured IND clearance and CTA authorization for the Phase 1b/2a BEACON study of briquilimab in CSU and successfully dosed the first patient.
  • Our achievements in 2023 set the stage for a transformational year ahead with multiple key clinical milestones on the horizon across multiple indications.
  • Strengthened the organization with key leadership appointments including Thomas Wiggans as Chairperson of the Board of Directors, Scott Brun, M.D.

Vaccine Adjuvants Market by Product, Route of Administration, Disease Type, Application, Application Category and Region - Global Forecast to 2027 - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 6, 2022
Infectious Diseases, Pharmaceutical, Health, GSK, Prevalence, Growth, Infection, Vaccine, CAGR, Prominence, Commercial, Associated British Foods, Investment, Anthrax Vaccine Immunization Program, Immune system, Administration, InvivoGen, CSL Limited, Awareness, Particulates, Research, Merck Group, Pathogen, Antigen, Croda International, COVID-19, USD, Route of administration, Emulsion, Subcutaneous, Intramuscular injection, Cancer

The "Global Vaccine Adjuvants Market by Product (Particulate, Emulsions, Pathogen, Saponin), Route of Administration (Subcutaneous, Intramuscular), Disease Type (Infectious, Cancer), Application (Research, Commercial) & Application Category - Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Vaccine Adjuvants Market by Product (Particulate, Emulsions, Pathogen, Saponin), Route of Administration (Subcutaneous, Intramuscular), Disease Type (Infectious, Cancer), Application (Research, Commercial) & Application Category - Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.
  • The vaccine adjuvants market is projected to reach USD 16 Billion by 2027 from USD 1.5 Billion in 2022, at a CAGR of 1.7% during the forecast period.
  • The infectious diseases segment accounted for the largest share of the market in 2021.
  • In this region, China and Japan are the largest markets while India is projected to grow at a highest CAGR during the forecast period.

Saudi Arabia Human Insulin Market Report 2022-2027 Featuring Novo Nordisk, Sanofi, Baxter International, B Braun, Eli Lilly and Co, & Pfizer - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 21, 2022
Diabetes, Pharmaceutical, Health, Diabetes, Investment, World, Novo Nordisk, Awareness, Subcutaneous, Research, Government, Drug discovery, Route of administration, Risk, Eli Lilly, Type 2 diabetes, Administration, Patient, Oral, Insulin, Growth, Intravenous therapy, Prevalence, Pharmaceutical industry, Medical device, Weapon

Companies involved in the Saudi Arabia human insulin market are adopting competitive strategies such as partnerships, agreements, awareness campaigns, and research funding & grants to strengthen their product portfolio and sustain growth in Saudi Arabia human insulin market.

Key Points: 
  • Companies involved in the Saudi Arabia human insulin market are adopting competitive strategies such as partnerships, agreements, awareness campaigns, and research funding & grants to strengthen their product portfolio and sustain growth in Saudi Arabia human insulin market.
  • Key players in Saudi Arabia human insulin market are Novo Nordisk Saudi Arabia, Sanofi Saudi Arabia, Baxter International Saudi Arabia, B Braun Saudi Arabia, Eli Lilly and Company Saudi Arabia, Pfizer Saudi Arabia, among others.
  • To analyze the historical growth in the market size of Saudi Arabia human insulin market from 2017 to 2021.
  • To identify key sustainable strategies adopted by market players in Saudi Arabia human insulin market.

Gilead Announces Clinical Hold on Studies Evaluating Injectable Lenacapavir for HIV Treatment and Prevention Due to Vial Quality Concerns

Retrieved on: 
Wednesday, December 22, 2021
AIDS, Health, FDA, Hospitals, Clinical Trials, Pharmaceutical, Biotechnology, People, U.S. Securities and Exchange Commission, Birth, Pharmacokinetics, Subtypes of HIV, Intramuscular injection, Gilead Sciences, Trans, Medicine, Risk, Pre-exposure prophylaxis, Education, Distribution, Private Securities Litigation Reform Act, AIDS, Twitter, IND Rockaway Line, Efficacy, Sex, Woman, Rectum, LEN, Plasma protein binding, Female, Solution, Gender, Man, HIV, Cancer, Male, Adolescence, HIV-1, Research, File, FDA, Risk management, Pharmaceutical industry, Subcutaneous, Cisgender, Safety, Lenacapavir, Tolerability

Lenacapavir is Gileads potential first-in-class, investigational long-acting HIV-1 capsid inhibitor in development for the treatment and prevention of HIV-1 infection.

Key Points: 
  • Lenacapavir is Gileads potential first-in-class, investigational long-acting HIV-1 capsid inhibitor in development for the treatment and prevention of HIV-1 infection.
  • While most antivirals act on just one stage of viral replication, lenacapavir is designed to inhibit HIV-1 at multiple stages of its lifecycle.
  • For more than 30 years, Gilead has been a leading innovator in the field of HIV, driving advances in treatment, prevention and cure research.
  • For more information about Gilead, please visit the companys website at www.gilead.com , follow Gilead on Twitter (@Gilead Sciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

Global Subcutaneous Self-Administration Injection Devices Market Report 2021-2028 - ResearchAndMarkets.com

Retrieved on: 
Friday, October 29, 2021
Health, Medical Supplies, Medical Devices, Conditional sentence, Syringe, Subcutaneous, Technology, Industry, Pharmaceutical industry, Risk management

The "Injection Devices for Subcutaneous Self-Administration" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Injection Devices for Subcutaneous Self-Administration" report has been added to ResearchAndMarkets.com's offering.
  • For drugs designed to be administered by the patient, therapy-specific packaging is improving adherence and treatment outcomes.
  • In the area of delivery, reusable injection devices designed to accept prefilled syringes or drug cartridges are improving ease-of-use and increasing the alternative device share of the growing self-injection market.
  • Provides detailed analysis of subcutaneous drug products, drug delivery and device strategies, and product development factors
    Evaluates the impact of economic, technology, and regulatory factor

Global Hydrogel-based Drug Delivery System Market Analysis Report 2021-2028: Polymer Origin (Natural, Synthetic, Hybrid), Route (Subcutaneous, Ocular, Oral Cavity) - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 11, 2021
Medical Devices, Medical Supplies, Infectious Diseases, Hospitals, Chemicals, Plastics, Manufacturing, Cardiology, Health, Pharmaceutical, Gel, Half-life, Hydrogel, Innovation, USD, Patient, Chemistry, Pain management, CAGR, Medicine, Chapter Three, Administration, Porosity, Subcutaneous, Research, Nature, Asia, Cardiology, Oral, Fine chemical, Pharmaceutical industry, Healthcare

The "Hydrogel-based Drug Delivery System Market Size, Share & Trends Analysis Report by Polymer Origin (Natural, Synthetic, Hybrid), by Route (Subcutaneous, Ocular, Oral Cavity), by Region, and Segment Forecasts, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hydrogel-based Drug Delivery System Market Size, Share & Trends Analysis Report by Polymer Origin (Natural, Synthetic, Hybrid), by Route (Subcutaneous, Ocular, Oral Cavity), by Region, and Segment Forecasts, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.
  • The global hydrogel-based drug delivery system market size is anticipated to reach USD 10.6 billion by 2028, expanding at a CAGR of 7.5%
    Surging demand for controlled release drug delivery systems across many therapeutic areas is a key factor expected to contribute to market growth during the forecast period.
  • Hydrogel-based drug delivery systems deliver the therapeutic drug directly at the target site and in a sustained manner.
  • Hydrogel-based drug delivery systems are appealing and have been used in many branches of medicine such as oncology, pain management, immunology, cardiology, and wound management.

Antares Pharma to Present at the Raymond James Human Health Innovations Conference

Retrieved on: 
Tuesday, June 15, 2021
Steroids, Drugs, Chemical compounds, Androstanes, Triptans, Ketones, Testosterone enanthate, Testosterone, Sumatriptan, Teva Pharmaceuticals, Subcutaneous, Forward-looking statement

EWING, N.J., June 15, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the Company), a specialty pharmaceutical company, today announced that Robert F. Apple, President and Chief Executive Officer, is scheduled to present at the Raymond James Human Health Innovations Conference.

Key Points: 
  • EWING, N.J., June 15, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the Company), a specialty pharmaceutical company, today announced that Robert F. Apple, President and Chief Executive Officer, is scheduled to present at the Raymond James Human Health Innovations Conference.
  • Antares Pharmas FDA-approved products include XYOSTED (testosterone enanthate) injection, OTREXUP (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva.
  • This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
  • Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described.

Celltrion Healthcare launches Remsima™ SC, the world's first subcutaneous formulation of infliximab in Canada, for the treatment of people with rheumatoid arthritis

Retrieved on: 
Monday, June 7, 2021
Drugs, Health care, Pharmacology, Monoclonal antibodies, Immunosuppressants, TNF inhibitors, Janssen Biotech, Infliximab, Janssen Pharmaceutica, Celltrion, Subcutaneous, Autoinjector

Remsima SC is commercially available in Canada in 120 mg fixed dose as a pre-filled pen (auto-injector) and is administered as a bi-weekly subcutaneous injection.

Key Points: 
  • Remsima SC is commercially available in Canada in 120 mg fixed dose as a pre-filled pen (auto-injector) and is administered as a bi-weekly subcutaneous injection.
  • "Having a subcutaneous formulation of infliximab means patients can have a more flexible dosing schedule and control on how they receive their treatment."
  • CELLTRION CONNECT patient support program is designed to support patients, caregivers, and healthcare providers with access to Remsima SC.
  • Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a
    randomized phase I/III trial.

New Clinical and Real-World Data Evaluating Efficacy of AJOVY® (fremanezumab-vfrm) Injection Presented at 2021 American Headache Society (AHS) Annual Meeting

Retrieved on: 
Thursday, June 3, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, Dosage forms, Injection, Routes of administration, Comorbidity, Subcutaneous

Non-significant reductions in SBP and DBP were observed during the follow-up period (0.34 and 0.59, respectively [P = 0.8374 and 0.5624, respectively]).

Key Points: 
  • Non-significant reductions in SBP and DBP were observed during the follow-up period (0.34 and 0.59, respectively [P = 0.8374 and 0.5624, respectively]).
  • Among patients with comorbid HTN, no increases were observed in mean SBP and DBP levels with AJOVY treatment.
  • This poster, Real-World Impact of AJOVY Use on Clinical Outcomes Among Migraine Patients With Comorbid Depression, Anxiety or Hypertension, is included in the online program.
  • 225 mg monthly administered as one subcutaneous injection, or 675 mg every three months (quarterly), which is administered as three subcutaneous injections.

Antares Pharma to Present at the Jefferies Virtual Healthcare Conference

Retrieved on: 
Wednesday, May 26, 2021
Drugs, Steroids, Organic compounds, Androstanes, Ketones, Testosterone enanthate, Hepatotoxins, Teva Pharmaceuticals, Immunosuppressants, Sumatriptan, Testosterone, Subcutaneous

A live webcast of the presentation will be available under the For Investors section of the Antares Pharma website at www.antarespharma.com.

Key Points: 
  • A live webcast of the presentation will be available under the For Investors section of the Antares Pharma website at www.antarespharma.com.
  • Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address unmet needs in targeted therapeutic areas such as urology and endocrinology.
  • Antares Pharmas FDA-approved products include XYOSTED (testosterone enanthate) injection, OTREXUP (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva.
  • Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described.